Abstract Details

Title Immunohistochemical Analysis Reveals Sympathetic Column Involvement in the SOD1 (G93A) Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

Topic Autonomic Disorders

Presentation(s) P03 - (-)

Poster/Presentation
Number 029

Objective

Background BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal disorder caused by degeneration of motor neurons in the cerebral cortex, brain stem and spinal cord. Several clinical reports indicated sympathetic and parasympathetic dysfunction in ALS patients. In addition, we have recently reported elevated heart rate and blood pressure in transgenic (TG) mice carrying the SOD1 mutant form of the human SOD1 transgene (SOD1G93A) even prior to the appearance of motor symptoms.

Design/Methods DESIGN/METHODS: We performed an immunohistochemical study of the superior cervical ganglia (SCG) and adrenal glands (AG) in TG and littermate wild-type (WT) mice at the age of 75-80 days. SCG and AG sections were stained with antibodies against tyrosine hydroxylase (TH) and choline acetyltransferase (ChAT).

Results RESULTS: TH expression in AG revealed a 24% decrease in the SOD1G93A group compared to WT (p<0.0001), while ChAT expression in the SCG was reduced by 28% (p<0.0001). No significant differences were found for TH in SCG or for ChAT in AG.

Conclusions CONCLUSIONS: These results are consistent with preganglionic sympathetic denervation as a potential contributor to the abnormal sympathetic regulation in ALS.

Authors/Disclosures
Cortney Houtz, LPN PRESENTER	Ms. Houtz has nothing to disclose.
Nikolaos C. Grigoriadis, MD, PhD (Aristotle University of Thessaloniki, B' Dept of Neurology)	No disclosure on file
Lori Mayer, RN, DNP, MSN, MSCN (Lori Mayer DNP)	Ms. Mayer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen, Genentech, Novartis, Alexion, Celgene. Ms. Mayer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Genentech, Novartis, Alexion, Celgene. Ms. Mayer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen, Genentech, Novartis, Alexion, Celgene. Ms. Mayer has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Consortium of MS Centers.
	No disclosure on file
Vivian E. Drory, MD (Tel-Aviv Medical Center)	Prof. Drory has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Prof. Drory has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Prof. Drory has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Prof. Drory has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Prof. Drory has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medison Pharma. The institution of Prof. Drory has received research support from Neurosense Therapeutics. The institution of Prof. Drory has received research support from AB Science. The institution of Prof. Drory has received research support from Biogen. The institution of Prof. Drory has received research support from Neuralight.
	No disclosure on file
	No disclosure on file
Amos D. Korczyn, MD (Tel - Aviv University Medical School)	Dr. Korczyn has nothing to disclose.

��ɫ��

��ɫ��